Stockscreener 앱 받기
7.30
3.18%
-0.24
시간 외 거래:
7.29
-0.010
-0.14%
전일 마감가:
$7.54
열려 있는:
$7.33
하루 거래량:
30,949
Relative Volume:
1.46
시가총액:
$212.00M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-8.18%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$7.11
$7.7654
1주일 범위
$7.11
$8.46
52주 변동 폭
$7.11
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
명칭
Vyome Holdings Inc
전화
949-429-6680
주소
1001 CALLE AMANECER, SAN CLEMENTE
HIND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
7.30 | 212.00M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyome Holdings Inc 주식(HIND)의 최신 뉴스
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies - PharmiWeb.com
Vyome Holdings strengthens leadership team with industry veterans as it plans pivotal trial studies - MarketScreener
Vyome Holdings, Inc. Announces Executive Changes - MarketScreener
Vyome Holdings Completes Merger with Vyome Therapeutics - MSN
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity - biospace.com
Vyome Holdings Inc positive interim data from Phase 2 Study of VT-1953 in malignant fungating wounds - MarketScreener
Vyome’s VT-1953 shows significant reduction in cancer wound odor By Investing.com - Investing.com Australia
Vyome’s VT-1953 shows significant reduction in cancer wound odor - Investing.com
Vyome Holdings completes merger with Vyome Therapeutics and files financials By Investing.com - Investing.com UK
Vyome Holdings completes merger with Vyome Therapeutics and files financials - Investing.com
Vyome Holdings, Embryyo Technologies Partner on AI Medtech - Medical Product Outsourcing
Vyome, Embryyo form partnership to pursue AI-enabled medical devices - Medical Economics
US-based Vyome signs MoU with India’s leading medical device innovation studio Embryyo - BioSpectrum India
Vyome And Embryyo Sign MoU To Develop AI-Enabled Medical Devices - Sahyadri Startups
Vyome Holdings, Inc. Signs MoU with Embryyo Technologies - MarketScreener
Vyome, India's Embryyo Sign MOU to Pursue AI Medical Device Market; Shares up Pre-Bell - MarketScreener
Vyome partners with Embryyo to enter AI-enabled medical device market - Investing.com
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio - FinancialContent
Vyome Holdings expands at-the-market offering and appoints new auditor - Investing.com India
Vyome Holdings expands at-the-market offering and appoints new auditor By Investing.com - Investing.com South Africa
Vyome Holdings Amends Equity Distribution Agreement - TipRanks
Vyome Amends Equity Distribution Agreement with ReShape Lifesciences Inc. - AInvest
Vyome enters amendment no. 1 to equity distribution agreement - MarketScreener
Vyome to review strategic options for majority-owned Livechain By Investing.com - Investing.com Australia
Vyome to review strategic options for majority-owned Livechain - Investing.com
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update - MarketScreener
Vyome Debuts as HIND on Nasdaq, Strengthening US-India Innovation Ties - YourStory.com
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - MarketScreener
Vyome lists on Nasdaq as HIND after ReShape merger - The Times of India
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND - MarketScreener
Vyome Therapeutics Completes Merger With ReShape Lifesciences - MarketScreener
Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market - Investing.com Canada
Vyome to begin trading as Vyome Holdings under HIND symbol By Investing.com - Investing.com Australia
Health Care Stocks Climb As Deals And Results Grab Attention - Finimize
Breaking: Clinical-Stage Biotech Vyome Finalizes ReShape Merger, Set for Nasdaq Debut as HIND Tomorrow - Stock Titan
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why By Stocktwits - Investing.com India
Vyome announces Nasdaq approval of merger with ReShape Lifesciences - TipRanks
Vyome therapeutics to list on nasdaq as HIND after reshape merger - Investing.com Canada
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why - Asianet Newsable
Vyome to replace ReShape leadership as it prepares for Nasdaq listing - Investing.com Canada
Vyome to replace ReShape leadership as it prepares for Nasdaq listing By Investing.com - Investing.com South Africa
Vyome Announces New Board of Directors with Deep MIT and AI Ties - FinancialContent
ReShape Lifesciences Approves Asset Sale and Merger with Vyome Therapeutics - AInvest
ReShape Shareholders Approve Vyome Merger, Shares to Commence Trading on Nasdaq as Vyome Holdings, Inc. - AInvest
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics - Business Wire
ReShape Lifesciences Merger at Critical Stage: Stockholders Must Approve Asset Sale by August 7 - Stock Titan
ReShape Lifesciences Strategic Transformation: Board and Proxy Advisors Unite Behind Vyome Merger - Stock Titan
AUTOCANADA ANNOUNCES CONFERENCE CALL AND WEBCAST DETAILS FOR Q2 2025 FINANCIAL RESULTS - The Globe and Mail
ReShape Lifesciences Slashes Payroll by 23.4% While Fast-Tracking Vyome MergerKey Details Revealed - Stock Titan
ReShape Lifesciences Stock Soars On Distribution Agreement With Recon Supply, Draws Retail Applause By Stocktwits - Investing.com India
Vyome Holdings Inc (HIND) 재무 분석
Vyome Holdings Inc (HIND)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.93%
0.10%
자본화:
|
볼륨(24시간):